Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 14/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407464 | 0.89 | CDK4 (0.47) | HCRTR2CDK4CCND1 | |
| SCHEMBL2403499 | 0.88 | MPO (0.38) | HCRTR1HCRTR2CDK4CCND1 | |
| SCHEMBL1968997 | 0.88 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL2406456 | 0.87 | HTR1A (0.38) | HTR2AHCRTR1HCRTR2CDK4CCND1 | |
| SCHEMBL2408924 | 0.87 | HTR1A (0.42) | HTR2AHCRTR2CDK4CCND1 | |
| SCHEMBL2405605 | 0.87 | CDK4 (0.39) | HTR2AHCRTR1HCRTR2CDK4CCND1 | |
| SCHEMBL2407843 | 0.87 | ICMT (0.41) | HTR2AHTR2CHTR2BHCRTR1HCRTR2 | |
| SCHEMBL2406567 | 0.85 | HTR2A (0.41) | HTR2AHTR2CHTR2BHCRTR1HCRTR2 | |
| SCHEMBL2404560 | 0.84 | ICMT (0.39) | HTR2AHTR2CHTR2BHCRTR1HCRTR2 | |
| SCHEMBL2408939 | 0.84 | HCRTR1 (0.39) | HCRTR1HCRTR2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HTR2A 46/4885HTR2C 80/4885HTR2B 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.